May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Eficacy of periocular carboplatin in a xenograft model of vitreous seeding human retinoblastoma.
Author Affiliations & Notes
  • R.A. P. De Carvalho
    Ophthalmology, Johns Hopkins University, Baltimore, MD
  • M. Taban
    Ophthalmology, University of California, Irvine, Irvine, CA
  • O. Kalous
    Ophthalmology, Children Hospital of Los Angeles, Los Angeles, CA
  • P. Reynolds
    Ophthalmology, Children Hospital of Los Angeles, Los Angeles, CA
  • N. Rao
    Ophthalmology, University of Southern California, Los Angeles, CA
  • A.L. Murphree
    Ophthalmology, Children Hospital of Los Angeles, Los Angeles, CA
  • Footnotes
    Commercial Relationships  R.A.P. De Carvalho, None; M. Taban, None; O. Kalous, None; P. Reynolds, None; N. Rao, None; A.L. Murphree, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5192. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.A. P. De Carvalho, M. Taban, O. Kalous, P. Reynolds, N. Rao, A.L. Murphree; Eficacy of periocular carboplatin in a xenograft model of vitreous seeding human retinoblastoma. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5192.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the efficacy of periocular carboplatin in a xenograft model of vitreous seeding retinoblastoma using a carboplatin–sensitive human cell line. Methods: To develop the vitreous seeding model of retinoblastoma, human tumor cells, previously shown in vitro to be sensitive to carboplatin (CHLA 203), were injected into the vitreous cavity of nude rats, unilaterally. To test the hypothesis that periocular injections are efficacious in treating intraocular retinoblastoma as previously published, 22 animals with vitreous seeding disease in one eye were randomized into 4 groups: placebo, carboplatin at doses of 200 ug, 500 ug, or 1 mg. The injections were administered twice a week for 4 weeks. Ophthalmoscopic evaluation was performed before and after treatment. Animals were euthanized 1 month after the last injection. Masked investigators graded the clinical and histopathological findings. Response to treatment was computed based on the scores before and after the injection for both clinical and histopathological findings. Frequency of complete and partial tumor regression was compared between groups using chi–square test. Simple and multiple linear regression models were applied to analyze the association between carboplatin doses and clinical, and histopathological findings after treatment. A type–I error smaller than 5% was adopted for statistical significance. Results: No animal responded to any of the concentrations of carboplatin and saline solution. Multiple and linear regression models did not demonstrate statistical significance of any association between dose of carboplatin and outcome variables (p > 0.1). Conclusions: Periocular carboplatin was not effective in this model using a carboplatin–sensitive cell line, in contradistinction to previously published results using transgenic models. In efficacy studies, xenograft models using human cell lines should be considered in addition to or as an alternative to transgenic models.

Keywords: retinoblastoma • vitreous • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×